Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,827 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus.
Kawaoka T, Hiraga N, Takahashi S, Takaki S, Mitsui F, Tsuge M, Nagaoki Y, Kimura Y, Hashimoto Y, Katamura Y, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Aikata H, Tashiro H, Ohdan H, Chayama K. Kawaoka T, et al. Among authors: kawakami y. Scand J Gastroenterol. 2010 Dec;45(12):1488-96. doi: 10.3109/00365521.2010.505657. Epub 2010 Jul 22. Scand J Gastroenterol. 2010. PMID: 20662615
Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.
Jeong S, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Jeong S, et al. Among authors: kawakami y. World J Gastroenterol. 2007 Oct 21;13(39):5188-95. doi: 10.3748/wjg.v13.i39.5188. World J Gastroenterol. 2007. PMID: 17876889 Free PMC article. Clinical Trial.
Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.
Jeong SC, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Jeong SC, et al. Among authors: kawakami y. World J Gastroenterol. 2007 Oct 28;13(40):5343-50. doi: 10.3748/wjg.v13.i40.5343. World J Gastroenterol. 2007. PMID: 17879404 Free PMC article.
Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial.
Takaki S, Kawakami Y, Imamura M, Aikata H, Takahashi S, Ishihara H, Tsuji K, Aimitsu S, Kawakami H, Nakanishi T, Kitamoto M, Moriya T, Satoh K, Chayama K. Takaki S, et al. Among authors: kawakami y, kawakami h. Intervirology. 2007;50(6):439-46. doi: 10.1159/000114718. Epub 2008 Feb 4. Intervirology. 2007. PMID: 18253048 Clinical Trial.
Prospective study of short-term peginterferon-alpha-2a monotherapy in patients who had a virological response at 2 weeks after initiation of interferon therapy.
Jeong S, Kawakami Y, Kitamoto M, Ishihara H, Tsuji K, Aimitsu S, Kawakami H, Uka K, Takaki S, Kodama H, Waki K, Imamura M, Aikata H, Takahashi S, Chayama K. Jeong S, et al. Among authors: kawakami y, kawakami h. J Gastroenterol Hepatol. 2008 Apr;23(4):541-5. doi: 10.1111/j.1440-1746.2008.05356.x. J Gastroenterol Hepatol. 2008. PMID: 18397484 Clinical Trial.
Etiology and outcome of acute liver failure: retrospective analysis of 50 patients treated at a single center.
Hiramatsu A, Takahashi S, Aikata H, Azakami T, Katamura Y, Kawaoka T, Uka K, Yamashina K, Takaki S, Kodama H, Jeong SC, Imamura M, Kawakami Y, Chayama K. Hiramatsu A, et al. Among authors: kawakami y. J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 1):1216-22. doi: 10.1111/j.1440-1746.2008.05402.x. Epub 2008 Jul 10. J Gastroenterol Hepatol. 2008. PMID: 18637059
Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: a randomized clinical trial.
Kawaoka T, Kawakami Y, Tsuji K, Ito H, Kitamoto M, Aimitsu S, Kawakami H, Jeong SC, Imamura M, Aikata H, Takahashi S, Chayama K. Kawaoka T, et al. Among authors: kawakami y, kawakami h. J Gastroenterol Hepatol. 2009 Mar;24(3):366-71. doi: 10.1111/j.1440-1746.2008.05650.x. Epub 2008 Nov 20. J Gastroenterol Hepatol. 2009. PMID: 19032459 Clinical Trial.
Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy.
Mori N, Imamura M, Kawakami Y, Saneto H, Kawaoka T, Takaki S, Aikata H, Takahashi S, Chayama K; Hiroshima Liver Study Group. Mori N, et al. Among authors: kawakami y. J Med Virol. 2009 Apr;81(4):640-9. doi: 10.1002/jmv.21438. J Med Virol. 2009. PMID: 19235866 Clinical Trial.
2,827 results